About HLB LifeScience
HLB LifeScience is a company based in Seongnam-si (South Korea) founded in 1998. The company has 169 employees as of December 31, 2024. HLB LifeScience has completed 1 acquisition, including AIM. HLB LifeScience operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Seongnam-si, South Korea
- Employees 169 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Hlb Life Science Co.,Ltd.
-
Annual Revenue
$69.32 M (USD)4.34as on Dec 31, 2024
-
Net Profit
$4.16 M (USD)0as on Dec 31, 2024
-
EBITDA
-$10.25 M (USD)15.12as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
169
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of HLB LifeScience
HLB LifeScience is a publicly listed company on the KRX with ticker symbol 067630 in South Korea, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of HLB LifeScience
Detailed funding history for HLB LifeScience
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HLB LifeScience
HLB LifeScience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AIM.
Investment portfolio details for HLB LifeScience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Automated wealth management is delivered via mobile robo-advisor app.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for HLB LifeScience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - HLB LifeScience
Detailed financials for HLB LifeScience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hlb Lifescience Comparisons
Peer comparison for HLB LifeScience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HLB LifeScience
HLB LifeScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of HLB LifeScience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hlb Lifescience
Complete news archive for HLB LifeScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HLB LifeScience
HLB LifeScience was founded in 1998.
HLB LifeScience is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Yang Gon Jin is the current CEO of HLB LifeScience.
As of Dec 31, 2024, the latest employee count at HLB LifeScience is 169.
Annual revenue of HLB LifeScience is $69.32M as on Dec 31, 2024.
Founded in 1998 and based in Seongnam-si, South Korea, therapeutics for oncology are developed by HLB LifeScience in the biopharmaceutical sector. Focus is placed on treatments such as Rivoceranib for stomach and liver cancers, Pyrotinib for non-small cell lung cancer, and other anticancer agents. Operations center on research and development to address various cancer types through targeted drug innovations.
HLB LifeScience's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Yes, HLB LifeScience is publicly traded on KRX under the ticker symbol 067630.
HLB LifeScience has made 1 acquisition, including AIM.
The ticker symbol of HLB LifeScience is 067630 on KRX.